|MDACC Study No:||2012-0740 (clinicaltrials.gov NCT No: NCT01585688)|
|Title:||A Phase I/II Study of Immunotherapy with hLL1-DOX in Patients|
with Non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic
|Principal Investigator:||Felipe Samaniego|
|Study Description:||The goal of the Phase I part of this clinical research study is to find the |
highest tolerable dose of hLL1-DOX that can be given to patients with NHL or
The goal of Phase II is to learn if hLL1-DOX can help control NHL or CLL. The
safety of this drug will also be studied.
hLL1-DOX is made up of hLL1 (an antibody - a substance that can locate and bind
to foreign objects [such as cancer cells] wherever they are in the body) and
doxorubicin (a drug designed to stop the growth of cancer cells). This
combination may cause the cancer cells to die.